Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID‐19 vaccination

Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause. We report a 67‐year‐old man with Pityriasis rubra pilaris might induced by COVID‐19 vaccination. The patient developed the lesions after the first dose of vaccine and significantly aggravated after the second dose. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ya‐ting, Wang, Shang‐shang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349810/
https://www.ncbi.nlm.nih.gov/pubmed/35941937
http://dx.doi.org/10.1002/ski2.139
_version_ 1784762154595909632
author Liu, Ya‐ting
Wang, Shang‐shang
author_facet Liu, Ya‐ting
Wang, Shang‐shang
author_sort Liu, Ya‐ting
collection PubMed
description Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause. We report a 67‐year‐old man with Pityriasis rubra pilaris might induced by COVID‐19 vaccination. The patient developed the lesions after the first dose of vaccine and significantly aggravated after the second dose. He had poor effect and liver function impairment developed after acitretin used, but achieved satisfactory efficacy after replacement to ixekizumab, an interleukin‐17A inhibitor.
format Online
Article
Text
id pubmed-9349810
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93498102022-08-04 Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID‐19 vaccination Liu, Ya‐ting Wang, Shang‐shang Skin Health Dis Case Reports Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause. We report a 67‐year‐old man with Pityriasis rubra pilaris might induced by COVID‐19 vaccination. The patient developed the lesions after the first dose of vaccine and significantly aggravated after the second dose. He had poor effect and liver function impairment developed after acitretin used, but achieved satisfactory efficacy after replacement to ixekizumab, an interleukin‐17A inhibitor. John Wiley and Sons Inc. 2022-06-16 /pmc/articles/PMC9349810/ /pubmed/35941937 http://dx.doi.org/10.1002/ski2.139 Text en © 2022 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Liu, Ya‐ting
Wang, Shang‐shang
Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID‐19 vaccination
title Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID‐19 vaccination
title_full Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID‐19 vaccination
title_fullStr Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID‐19 vaccination
title_full_unstemmed Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID‐19 vaccination
title_short Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID‐19 vaccination
title_sort ixekizumab successfully treated severe pityriasis rubra pilaris after covid‐19 vaccination
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349810/
https://www.ncbi.nlm.nih.gov/pubmed/35941937
http://dx.doi.org/10.1002/ski2.139
work_keys_str_mv AT liuyating ixekizumabsuccessfullytreatedseverepityriasisrubrapilarisaftercovid19vaccination
AT wangshangshang ixekizumabsuccessfullytreatedseverepityriasisrubrapilarisaftercovid19vaccination

Ejemplares similares